Merck Gets FDA Priority Review for Investigational Ebola Zaire Virus Vaccine
17 September 2019 - 1:29PM
Dow Jones News
By Colin Kellaher
Merck & Co. (MRK) on Tuesday said the U.S. Food and Drug
Administration has accepted and granted priority review to its
biologics license application for V920, an investigational vaccine
for the Ebola Zaire virus.
The Kenilworth, N.J., drug maker said the agency set a target
action date of March 14, 2020.
The FDA grants priority review to medicines that have the
potential to provide significant improvements in the treatment of a
serious disease, and the designation shortens the review period to
six months from the standard 10 months.
Merck said it continues to supply investigational V920 Ebola
vaccine doses to meet outbreak response needs in the Democratic
Republic of Congo and neighboring countries.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 17, 2019 07:14 ET (11:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
